Export Ready — 

New molecular targets for PET and SPECT imaging in neurodegenerative diseases

Bibliographic Details
Main Author: Benadiba,Marcel
Publication Date: 2012
Other Authors: Luurtsema,Gert, Wichert-Ana,Lauro, Buchpigel,Carlos Alberto, Busatto Filho,Geraldo
Format: Article
Language: eng
Source: Brazilian Journal of Psychiatry (São Paulo. 1999. Online)
Download full: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-44462012000600003
Summary: The pathophysiology of neurodegenerative diseases (ND) such as Alzheimer's disease (AD) and Parkinson's disease (PD) has not yet been completely elucidated. However, in the past few years, there have been great knowledge advances about intra-and extracellular proteins that may display impaired function or expression in AD, PD and other ND, such as amyloid beta (Aβ), α-synuclein, tau protein and neuroinflammatory markers. Recent developments in the imaging techniques of positron emission tomography (PET) and single photon emission computed tomography (SPECT) now allow the non-invasive tracking of such molecular targets of known relevance to ND in vivo. This article summarizes recent findings of PET and SPECT studies using these novel methods, and discusses their potential role in the field of drug development for ND as well as future clinical applications in regard to differential diagnosis of ND and monitoring of disease progression.
id ABP-1_841f2e785c535666e54dce24a36fa399
oai_identifier_str oai:scielo:S1516-44462012000600003
network_acronym_str ABP-1
network_name_str Brazilian Journal of Psychiatry (São Paulo. 1999. Online)
repository_id_str
spelling New molecular targets for PET and SPECT imaging in neurodegenerative diseasesPositron emission tomographySingle photon emission tomographyNeurodegenerative diseasesNeuroinflammationBrain lipid metabolismThe pathophysiology of neurodegenerative diseases (ND) such as Alzheimer's disease (AD) and Parkinson's disease (PD) has not yet been completely elucidated. However, in the past few years, there have been great knowledge advances about intra-and extracellular proteins that may display impaired function or expression in AD, PD and other ND, such as amyloid beta (Aβ), α-synuclein, tau protein and neuroinflammatory markers. Recent developments in the imaging techniques of positron emission tomography (PET) and single photon emission computed tomography (SPECT) now allow the non-invasive tracking of such molecular targets of known relevance to ND in vivo. This article summarizes recent findings of PET and SPECT studies using these novel methods, and discusses their potential role in the field of drug development for ND as well as future clinical applications in regard to differential diagnosis of ND and monitoring of disease progression.Associação Brasileira de Psiquiatria2012-10-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-44462012000600003Brazilian Journal of Psychiatry v.34 suppl.2 2012reponame:Brazilian Journal of Psychiatry (São Paulo. 1999. Online)instname:Associação Brasileira de Psiquiatria (ABP)instacron:ABP10.1016/j.rbp.2012.08.002info:eu-repo/semantics/openAccessBenadiba,MarcelLuurtsema,GertWichert-Ana,LauroBuchpigel,Carlos AlbertoBusatto Filho,Geraldoeng2013-01-17T00:00:00Zoai:scielo:S1516-44462012000600003Revistahttp://www.bjp.org.br/ahead_of_print.asphttps://old.scielo.br/oai/scielo-oai.php||rbp@abpbrasil.org.br1809-452X1516-4446opendoar:2013-01-17T00:00Brazilian Journal of Psychiatry (São Paulo. 1999. Online) - Associação Brasileira de Psiquiatria (ABP)false
dc.title.none.fl_str_mv New molecular targets for PET and SPECT imaging in neurodegenerative diseases
title New molecular targets for PET and SPECT imaging in neurodegenerative diseases
spellingShingle New molecular targets for PET and SPECT imaging in neurodegenerative diseases
Benadiba,Marcel
Positron emission tomography
Single photon emission tomography
Neurodegenerative diseases
Neuroinflammation
Brain lipid metabolism
title_short New molecular targets for PET and SPECT imaging in neurodegenerative diseases
title_full New molecular targets for PET and SPECT imaging in neurodegenerative diseases
title_fullStr New molecular targets for PET and SPECT imaging in neurodegenerative diseases
title_full_unstemmed New molecular targets for PET and SPECT imaging in neurodegenerative diseases
title_sort New molecular targets for PET and SPECT imaging in neurodegenerative diseases
author Benadiba,Marcel
author_facet Benadiba,Marcel
Luurtsema,Gert
Wichert-Ana,Lauro
Buchpigel,Carlos Alberto
Busatto Filho,Geraldo
author_role author
author2 Luurtsema,Gert
Wichert-Ana,Lauro
Buchpigel,Carlos Alberto
Busatto Filho,Geraldo
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Benadiba,Marcel
Luurtsema,Gert
Wichert-Ana,Lauro
Buchpigel,Carlos Alberto
Busatto Filho,Geraldo
dc.subject.por.fl_str_mv Positron emission tomography
Single photon emission tomography
Neurodegenerative diseases
Neuroinflammation
Brain lipid metabolism
topic Positron emission tomography
Single photon emission tomography
Neurodegenerative diseases
Neuroinflammation
Brain lipid metabolism
description The pathophysiology of neurodegenerative diseases (ND) such as Alzheimer's disease (AD) and Parkinson's disease (PD) has not yet been completely elucidated. However, in the past few years, there have been great knowledge advances about intra-and extracellular proteins that may display impaired function or expression in AD, PD and other ND, such as amyloid beta (Aβ), α-synuclein, tau protein and neuroinflammatory markers. Recent developments in the imaging techniques of positron emission tomography (PET) and single photon emission computed tomography (SPECT) now allow the non-invasive tracking of such molecular targets of known relevance to ND in vivo. This article summarizes recent findings of PET and SPECT studies using these novel methods, and discusses their potential role in the field of drug development for ND as well as future clinical applications in regard to differential diagnosis of ND and monitoring of disease progression.
publishDate 2012
dc.date.none.fl_str_mv 2012-10-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-44462012000600003
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-44462012000600003
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1016/j.rbp.2012.08.002
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Associação Brasileira de Psiquiatria
publisher.none.fl_str_mv Associação Brasileira de Psiquiatria
dc.source.none.fl_str_mv Brazilian Journal of Psychiatry v.34 suppl.2 2012
reponame:Brazilian Journal of Psychiatry (São Paulo. 1999. Online)
instname:Associação Brasileira de Psiquiatria (ABP)
instacron:ABP
instname_str Associação Brasileira de Psiquiatria (ABP)
instacron_str ABP
institution ABP
reponame_str Brazilian Journal of Psychiatry (São Paulo. 1999. Online)
collection Brazilian Journal of Psychiatry (São Paulo. 1999. Online)
repository.name.fl_str_mv Brazilian Journal of Psychiatry (São Paulo. 1999. Online) - Associação Brasileira de Psiquiatria (ABP)
repository.mail.fl_str_mv ||rbp@abpbrasil.org.br
_version_ 1754212555932303360